A biotechnology company in China has unveiled an experimental anti-aging pill that it believes could one day contribute to significantly longer human lifespans. However, scientists emphasize that such claims have not yet been validated through human studies.
Shenzhen-based Lonvi Biosciences is currently developing a capsule containing Procyanidin C1 (PCC1), a naturally occurring compound found in grape seed extract. The substance has attracted interest within the scientific community for its potential role in combating age-related cellular decline.
According to the company, PCC1 works by targeting senescent cells, often referred to as “zombie cells.” These cells no longer divide but remain active within the body, where they can contribute to chronic inflammation and various age-related conditions.
Lonvi Biosciences believes that removing or reducing these cells could support healthier aging and potentially extend lifespan. The company has even suggested that advances in longevity science could make lifespans of up to 150 years possible in the future.
Despite the optimism, researchers caution that there is currently no scientific evidence showing PCC1 can extend human life to such an extent.
Much of the excitement surrounding the compound stems from a 2021 study published in Nature Metabolism, which found that PCC1 improved health outcomes and increased lifespan in laboratory mice by eliminating senescent cells.
While the findings are promising, experts note that successful results in animal models do not automatically translate to humans. Extensive clinical trials involving human participants would be required before any conclusions about lifespan extension can be drawn.
Scientists also stress that the existing body of evidence remains limited. Although PCC1 represents an intriguing avenue in longevity research, there is no verified clinical proof that it can dramatically increase human lifespan.
The development reflects a broader global effort to explore treatments that address the biological processes of aging itself rather than focusing solely on individual diseases. China, along with several other countries, has seen growing investment in biotechnology companies researching longevity and age-related health interventions.
For now, Lonvi Biosciences’ anti-aging capsule remains an experimental product. Its true effectiveness and safety will ultimately depend on the outcomes of future human clinical studies and scientific evaluation.
